Research
Hormonal
Tirzepatide (15mg weekly) achieves 20.9% weight loss, with 50-57% of users losing >= 20% body weight, rivaling bariatric surgery.
Tirzepatide 15mg weekly can lead to ~21% weight loss. Over half of users lose 20% or more. This is a powerful option for those with comorbidities.
StrongSupportsVERY_HIGH confidence
The intervention resulted in substantial and dose-dependent reductions in body weight, with mean losses of 15.0%, 19.5%, and 20.9%, respectively... Notably, 50–57% of individuals in the 10 mg and 15 mg groups achieved a weight reduction of 20% or more—an outcome previously attainable primarily through metabolic surgery
Why this rating
Phase 3 RCT data.
Source
Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines
Safi Alqatari et al. · Medicina · 2025
DOI 10.3390/medicina61071292
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Emerging pharmacotherapies, specifically GLP-1 receptor agonists and multi-agonists, induce 15-25% weight loss, challenging the necessity of bariatric surgery for patients with BMI 30-40 kg/m2.Good
- Current bariatric surgery guidelines (BMI >= 35, or 30-34.9 with comorbidities) may need re-evaluation due to the efficacy of pharmacotherapy.Good
- Retatrutide (12mg weekly) achieves 24.2% weight loss, rivaling bariatric surgery outcomes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →